Review

Sulfasalazine in dermatology: A lesser explored drug with broad therapeutic potential

Sabha Mushtaq MD, Rashmi Sarkar MD

a Department of Dermatology, Venereology & Leprology, Government Medical College, Jammu, Jammu & Kashmir, India
b Department of Dermatology, Venereology & Leprology, Maulana Azad Medical College, New Delhi, India

Abstract

Sulfasalazine is an aminosalicylate primarily used in the treatment of rheumatoid arthritis and ulcerative colitis. Its immunomodulatory, anti-inflammatory, and antiproliferative properties make it a potential therapeutic option for various dermatological disorders. Owing to its wide range of effects, it is often used off-label in dermatological diseases, such as alopecia areata, psoriasis and psoriatic arthritis, lichen planus, and pemphigus. However, the level of evidence supporting its efficacy and safety in dermatology is limited. More research is needed to uncover the full potential of sulfasalazine in dermatology. The present article is a detailed review of the pharmacology, modes of action, side effects, and contraindications of sulfasalazine, along with an up-to-date review of the evidence underlying its use in various dermatological conditions.

© 2020 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

Introduction .................................................. 192
History ....................................................... 192
Pharmacokinetics .......................................... 192
Absorption .................................................. 193
Distribution ................................................ 193
Metabolism and excretion ............................. 193
Mechanism of action ..................................... 193
Dermatological uses ....................................... 193
Psoriasis and psoriatic arthritis ...................... 193
Alopecia areata ........................................... 193
Lichen planus ............................................. 194
Immunobullous disorders ............................... 193
Urticaria and angioedema ............................. 195
Pyoderma gangrenosum, erythema elevatum diutinum, and Behcet’s disease ...................... 195
Anosmia blanche .......................................... 195
Discoid lupus erythematosus ......................... 195
Morphea and lichen sclerosus et atrophicus ......... 195
Miscellaneous ............................................ 195
Dosage and administration ............................ 195
Adverse effects ........................................... 196
Gastrointestinal and hepatic .......................... 196
Hematologic ............................................... 196
Dermatologic ............................................ 196
Central nervous system ............................... 196
Introduction

Sulfasalazine (SSZ; salazopyrin, sulfasalazopyridine, salicylazo-sulfapyridine) is a U.S. Food and Drug Administration–approved disease-modifying antirheumatic drug (DMARD) commonly used in the treatment of rheumatoid arthritis and ulcerative colitis (Rains et al., 1995). Owing to its anti-inflammatory action, SSZ is used off-label in a wide spectrum of dermatological diseases; however, there is dearth of literature on its use in dermatology.

History

SSZ was devised by Dr. Nana Svartz, a Scandinavian rheumatologist and professor of medicine at the Karolinska Institute in Stockholm, in cooperation with Swedish pharmaceutical company Pharmacia in 1941. It was an attempt to treat rheumatoid arthritis (then known as rheumatic polyarthritis), which was believed to be a disease of bacterial origin. It was observed that when given concomitantly, sulfonamides and aspirin did not produce concrete results, which shifted the research focus to combining the two agents chemically to produce an antibiotic that would have an affinity for connective tissue. The result was the drug SSZ, which was first tried in rheumatic polyarthritis with impressive results and later in ulcerative colitis (Dover, 1971; Svartz, 1948; Watkinson, 1986). The use of SSZ in dermatology can be traced back to 1971 when it was first used in scleroderma (Dover, 1971).

Pharmacokinetics

Absorption

SSZ is the combination of a sulfonamide (sulfapyridine) and mesalazine (mesalamine, 5-aminosalicylic acid) covalently linked by an azo bond. It is absorbed in the small intestine with an oral bioavailability of approximately 10% to 30%. SSZ that reaches the large bowel undergoes azoreduction by bacterial azoreductases to release sulfapyridine and mesalazine. Sulfapyridine is almost fully (>90%) absorbed, whereas mesalazine undergoes only 20% to 30% absorption, and the remainder is eliminated in the feces (Fig. 1; Plosker and Croom, 2005; Rains et al., 1995).

Distribution

Absorbed sulfasalazine is distributed throughout the body but does not cross the blood–brain barrier. Both SSZ and sulfapyridine cross the placenta and are found in breast milk. Breast milk con-
centrations of sulfapyridine are approximately 40% of those seen in plasma, but SSZ concentrations are negligible. Plasma concentrations of mesalazine are very low, and it is therefore unlikely to be found in breast milk. Both sulfapyridine and SSZ distribute to synovial fluid, with concentrations generally lower than those found in plasma. The peak plasma level of sulfapyridine is attained later than SSZ. The plasma protein binding is up to 99% for SSZ and found in plasma. The peak plasma level of sulfapyridine is attained up to 99% for SSZ and 50% for sulfapyridine (Rains et al., 1995).

Metabolism and excretion

Systemically absorbed sulfasalazine is metabolized to some extent in the liver to sulfapyridine and mesalazine (U.S. National Library of Medicine, 2001); a small proportion of an administered dose of SSZ is eliminated unchanged in the urine (Rains et al., 1995; Tett, 1993). Sulfapyridine is primarily metabolized by acetylation in the liver to form N-acetyl-sulfapyridine (inactive), some of which is eliminated in the urine. Sulfapyridine and its N-acetyl metabolite also undergo hydroxylation and glucuronidation; the glucuronide conjugates and the hydroxylated metabolites (5-hydroxy-sulfapyridine and N-acetyl-5-hydroxy-sulfapyridine) are eliminated in the urine (Rains et al., 1995; Tett, 1993; U.S. National Library of Medicine, 2001).

Mesalazine is mainly (70%–80%) eliminated unchanged in the feces, but it also undergoes acetylation to form N-acetyl-mesalazine (inactive), which is eliminated in the urine (Fig. 1). The metabolism of sulfapyridine is affected by the acetylator phenotype. In the Caucasian population, there is an approximately equal distribution in fast and slow acetylators (Plosker and Croom, 2005; Tett, 1993). The elimination half-life of sulfapyridine ranges between 5 and 18 hours and is approximately 50% to 100% longer in slow acetylators than in fast acetylators. Slow acetylators have response rates ranging from 250 mg/day to 3 g/day.

Reductions have been observed in ICAM-1 expression, leukotriene synthesis, and in the number of intraepidermal and dermal T lymphocytes, as well as T-helper CD4 cells in the skin biopsy specimens of patients affected by psoriasis and treated with SSZ (Gupta, 1990). SSZ was also found to be effective in a case of acrodermatitis continua of Hallopeau (Li et al., 2018a). SSZ has been tried successfully alone and in combination with pentoxifylline in patients with psoriasis (Bharti and Girgla, 1996; El-Mofty et al., 2011; Gupta, 1990; Gupta et al., 1989) and psoriatic arthritis (Jones et al., 2000; Marguerie et al., 2002) owing to its anti-inflammatory and antiproliferative action. The prescribed dose ranges from 1500 mg/day to 3 g/day.

Mechanism of action

The sulfa moiety is known to have antimicrobial properties, whereas the salicylate component acts as an anti-inflammatory agent. The mechanism of action of SSZ is summarized in Table 1 (Akahoshi et al., 1997; Bissonnette et al., 1996; Camp, 1992; Cannella and O’Dell, 2017; Feeley et al., 1999; Fujiwara et al., 1990; Gadangi et al., 1996; Gupta, 1990; Halasz, 1990; Hashimoto et al., 1991; Hirohata et al., 2002; Kang et al., 1999; Plosker and Croom, 2005; Pruzański et al., 1997; Rodenburg et al., 2000; Smedegård and Björk, 1995; Yamazaki et al., 1991).

Psoriasis and psoriatic arthritis

SSZ has been tried successfully alone and in combination with pentoxifylline in patients with psoriasis (Bharti and Girgla, 1996; El-Mofty et al., 2011; Gupta, 1990; Gupta et al., 1989) and psoriatic arthritis (Jones et al., 2000; Marguerie et al., 2002) owing to its anti-inflammatory and antiproliferative action. The prescribed dose ranges from 1500 mg/day to 3 g/day.

Alopecia areata

SSZ in a dose of 500 mg twice daily for 1 month, 1 g twice daily for 1 month, and then 1.5 g twice daily for a maximum of 3 months was used in recalcitrant cases of alopecia areata with good response in 27% of cases (Aghaie, 2008). Ellis et al. (2002) reported a 23% response in severe cases of alopecia areata (Ellis et al. 2002).

Lichen planus

In a prospective uncontrolled study of 20 patients with lichen planus (LP), SSZ at initial doses of 1.5 g/day and increased by 0.5 g/week to 3 g/day for 4 to 16 weeks yielded a complete response in 13 patients and a partial response in 7 patients. Patients with mucosal LP showed a poor response (Bauza et al., 2005).

A randomized, double-blind, placebo-controlled, prospective study of 52 patients with LP concluded that SSZ is a relatively safe and effective alternative treatment option for generalized LP (Omidian et al., 2010). SSZ has also been tried in a topical formula-
| S. No. | Dermatological disease | Study (year) | Sample size | Maximum daily dose | Maximum duration of treatment | Outcome | Adverse effects reported |
|-------|-----------------------|-------------|-------------|-------------------|-----------------------------|---------|-------------------------|
| 1.    | Psoriasis             | Uncontrolled open-label study (Gupta et al., 1989) | 32          | 3 g               | 8 weeks                     | Twenty-four patients completed the treatment, and 17 had modest to marked improvement or clearing. | Nausea, indigestion, diarrhea, fatigue, cutaneous reaction |
|       | Double-blind placebo-controlled randomized study (Gupta et al, 1990) | 50          | 4 g         | 8 weeks           |                              | In the SSZ group, 7 of 17 patients had marked, 7 of 17 had moderate, and 3 of 17 had minimal improvement. | Cutaneous reactions, nausea |
|       | Comparative randomized study (Bharti and Girgla, 1996) | 30          | 1.5 g       | 12 weeks          |                              | Efficacy was comparable for the 2 drugs: Decrease in mean EST in patients on methotrexate and SSZ therapy was 86.55% and 83.64% at 4 weeks and 92.86% and 92.13% at 12 weeks, respectively. | Transient rise in transaminases |
|       | Randomized controlled trial (El-Mofy et al., 2011) | 32          | 2 g         | 8 weeks           | Twenty-one of 32 patients completed treatment. The percentage reduction in PASI score achieved with methotrexate was significantly higher than that with SSZ alone, PTX alone, or the combined use of SSZ and PTX | Nausea |
| 2.    | Alopecia areata       | Retrospective record based on (Ellis et al., 2002) | 249         | 3 g               | Variable                     | Of the 19 patients who took SSZ for ≥ 3 months, 7 patients had excellent, 3 had slight, and 9 had no improvement | GI distress, rash, laboratory abnormalities, headache |
|       | Uncontrolled open-label study (Aghaei, 2008) | 26          | 3 g         | 6 months          | Twenty-two patients completed treatment. Overall, 15 of 22 patients (68.2%) responded to therapy. Six of 22 (27.3%) achieved complete hair regrowth, and 40.9% had partial hair regrowth. Of the 22 patients with complete and partial remission, 10 (45.5%) had partial or complete relapse | GI distress, cutaneous rash, leukopenia, poor glycemic control |
|       | Double-blind, randomized, placebo-controlled study (Omidian et al., 2010) | 52          | 2.5 g       | 6 weeks           | Twenty-three patients in the SSZ group and 21 patients in the placebo group evaluated for efficacy. | Skin rash, headache, GI distress, mild leucopenia |
| 3.    | Lichen planus         | Uncontrolled open-label study (Bauza et al., 2005) | 20          | 3 g               | 12 months                    | Complete responses were observed in 13 patients and partial responses in 7 patients. All patients reported an early resolution of the pruritus. No changes were detected in mucosal lichen planus | GI distress, cutaneous rash, leukopenia, poor glycemic control |
|       | Double-blind study (El-Darouti et al., 2009) | 64          | Topical SSZ 3 times/day +PTX 1.2 g3 | Variable | Seventeen patients (81%) reported improvement of discomfort and 12 patients (57%) had lesions decrease in size > 50% | Gastric pain, nausea, and headache |
|       | Uncontrolled, open-label study (Dogra et al., 2015) | 15          | SSZ 1.5 g (+PTX 1.2 g) | Variable | Forty-two patients received SSZ+PTX and 22 patients received placebo. A statistically significant decrease in serum levels of TNF-alpha in the SSZ group compared with those in the placebo group at 6 and 8 weeks. Significant clinical improvement was observed in patients in the SSZ group compared with those in the placebo group. | Skin rash, headache, GI distress, mild leucopenia |
| 4.    | Pemphigus vulgaris    | Uncontrolled open-label study (Jeong et al., 2016) | 21          | Topical SSZ 3 times/day SSZ 1.5 g (+PTX 1.2 g) | 4 weeks | Patients achieved remission period ranging from 6 months to 3 years | Nausea, vomiting, headache, and fatigue |
|       | Comparative, double-blind study (El-Darouti et al., 2009) | 64          | Variable |        | Seventeen patients (81%) reported improvement of discomfort and 12 patients (57%) had lesions decrease in size > 50% | NR |
|       | Uncontrolled, open-label study (Dogra et al., 2015) | 15          | SSZ 1.5 g (+PTX 1.2 g) | Variable | Forty-two patients received SSZ+PTX and 22 patients received placebo. A statistically significant decrease in serum levels of TNF-alpha in the SSZ group compared with those in the placebo group at 6 and 8 weeks. Significant clinical improvement was observed in patients in the SSZ group compared with those in the placebo group. | | NR |
| 5.    | Dermatitis herpetiformis | Case report (Willsteed et al., 2005) | 2           | 4 g               | Variable                     | Disease remained controlled with SSZ alone in four patients (45%). Two patients (22%) required adjunctive oral cyclophosphamide | GI discomfort, hemolysis |
| 6.    | Mucus membrane pemphigoid | Retrospective study (Doan et al., 2001) | 9           | 4 g               | Variable                     | Disease remained controlled with SSZ alone in four patients (45%). Two patients (22%) required adjunctive oral cyclophosphamide | GI discomfort, hemolysis |
| 7.    | Urticaria             | Retrospective study (McGirt et al, 2006) | 19          | 4 g               | 24 months                    | Fourteen patients (74%) reported significant improvement, four patients (21%) reported minimal improvement but were not satisfied with their symptom relief, and one patient (5%) reported worsening of symptoms | Headache, GI discomfort, leukopenia, elevated liver enzymes |
|       | Retrospective study (Orden et al, 2014) | 39          | 3 g         | 74 weeks (mean)   | Eight patients were excluded from the final analysis. Twenty-six patients (83.9%) showed an improvement in symptoms within the first 3 months, with 51.6% of patients becoming asymptomatic within the first 6 months of starting SSZ. Eleven patients (35.4%) achieved complete relief of symptoms after tapering off SSZ therapy. Five of the 31 patients (16.1%) failed treatment | Leucopenia, anaemia, raised transaminases, rhabdomyolysis |
|       | Case report (Engler et al., 1995) | 2           | 4 g         | Variable          | Eight patients were excluded from the final analysis. Twenty-six patients (83.9%) showed an improvement in symptoms within the first 3 months, with 51.6% of patients becoming asymptomatic within the first 6 months of starting SSZ. Eleven patients (35.4%) achieved complete relief of symptoms after tapering off SSZ therapy. Five of the 31 patients (16.1%) failed treatment | NR |
tion as a mouthwash in oral LP with good results (Jeong et al., 2016).

Immunobullous disorders

In a comparative double-blind study, a combination of SSZ and pentoxifylline used as adjuvant therapy in the treatment of PV induced a faster and more significant decrease in the serum level of tumor necrosis factor alpha (TNF-α), and this decrease was associated with rapid clinical improvement. These adjuvant therapies can replace cyclophosphamide, especially in younger patients, owing to their relatively fewer side effects (Dogra et al., 2015; El-Darouti et al., 2009).

SSZ is one of the first-line drugs for the management of ocular mucus membrane pemphigoid, alongside dapsone. Incidence of complications is also less frequently reported with SSZ than with dapsone (Doan et al., 2001; Sobolewska et al., 2013). However, limited data exist on the use of SSZ in other bullous disorders, such as dermatitis herpetiformis (Willsteed et al., 2005).

Urticaria and angioedema

Sulfasalazine has been effectively tried in antihistamine-resistant cases of chronic idiopathic urticaria and angioedema (McGirt et al., 2006; Orden et al., 2014). An isolated case has been reported of the usefulness of sulfasalazine in delayed pressure urticaria (Engler et al., 1995).

Pyoderma gangrenosum, erythema elevatum diutinum, and Behcet’s disease

Anecdotal cases have been reported on the successful use of SSZ in pyoderma gangrenosum and erythema elevatum diutinum (Bhat, 2012; Chen et al., 2017; Miranda, 2002). Low-dose SSZ has also been successfully used in a case of pyodermatitis-pyostomatitis vegetans (Li et al., 2018b). SSZ along with steroids is the first-line treatment for gastrointestinal Behcet’s disease (Alpsoy, 2012).

Atrophie blanche

Anecdotal reports exist on the use of SSZ in atrophie blanche (Bisalbutra and Kullavanijaya, 1993; Gupta et al., 1990).

Discoid lupus erythematosus

SSZ has been tried in the treatment of discoid lupus erythematosus. In one study comprising 11 cases, SSZ was found to be more effective in rapid acetylators (Artüz et al., 1996; Delaporte et al., 1997).

Morphea and lichen sclerosus et atrophicus

Generalized bullous morphea and generalized morphea with Lichen sclerosus et atrophicus was successfully treated with SSZ in occasional case reports (Micalizzi et al., 1996; Taveira et al., 1999).

Miscellaneous

Anecdotal reports exist on the use of SSZ in combination and sequential therapy with other DMARDs in the management of SAPHO syndrome with good response (Huber et al., 2009; Özen and Kalyoncu, 2011). The use of SSZ has also been reported in adult-onset still disease, but it should be used with caution owing to the high incidence of adverse effects (Jung et al., 2000).
Dosage and administration

SSZ is available in regular and enteric coated tablets of 500 mg and a suspension of 500 mg/ml. The dose is gradually titrated to minimize gastrointestinal adverse effects. The initial recommended dosage is 500 mg daily, escalated by 500 mg/day every week to the standard dose of 1500 to 3000 mg daily in divided doses. If a patient is intolerant of a new dose level, the dose should be reduced to a previously tolerated level for a further week and then increased again as appropriate. In pediatric patients, the initial dose is 10 to 12.5 mg/kg/day, which is increased weekly at 50 mg/kg/day in two divided doses until a maintenance of 2 g/day is achieved (Akil and Amos, 1995; Cannella and O’Dell, 2017).

Concomitant folic acid supplementation is advised because SSZ reduces folate absorption and is an inhibitor of the folate-dependent pathway. The dose should be reduced for patients with renal insufficiency (Cannella and O’Dell, 2017).

Adverse effects

Most adverse events due to SSZ occur during the first few months of treatment, and occurrences decrease with time. The most common adverse effects are gastrointestinal effects, headache, dizziness, and rash (Rains et al., 1995).

Gastrointestinal and hepatic

The most frequently reported adverse effects with SSZ therapy are gastrointestinal effects (nausea, vomiting, dyspepsia, anorexia, abdominal pain, and diarrhea). SSZ is therefore prescribed as enteric coated tablets for most patients to minimize gastrointestinal effects. Elevated levels of liver enzymes and hepatic dysfunction are reported less frequently and are mostly transient (Cannella and O’Dell, 2017).

Hematologic

Hematologic disturbances are reported in ≤3% of SSZ recipients and usually occur within the first 3 months. Leukopenia is the most common abnormality and usually reverses after discontinuing SSZ. The incidence of hematologic disturbances is higher in patients with rheumatoid arthritis than in patients receiving the drug for other diagnoses.

Macrocytosis due to folate deficiency and hemolysis have been reported with SSZ; its use should be avoided in patients with G6PD deficiency. Thrombocytopenia is rare (Cannella and O’Dell, 2017; Remlinger, 2012).

Dermatologic

The sulfapyridine moiety in SSZ is believed to be responsible for most of the hypersensitivity reactions that occur. Cutaneous rashes are reported in <5% of patients and are usually maculopapular, pruritic, and generalized (Cannella and O’Dell, 2017). Anecdotal reports exist of occurrences of erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, lichenoid eruption, lupus-like syndrome, and phototoxicity (Ghosh et al., 2013; Jullien et al., 1995; Santhanam and Singh, 2018; Tohyama et al., 1998; Tremblay et al., 2011).

Raynaud phenomenon, thinning of the hair, and cutaneous pigmentation have also been reported with SSZ use (Saigal et al., 2010; Brzezińska-Wcisło and Wcisło-Dziadecka, 2016; Gabazza et al., 1992).

Central nervous system

Headache and dizziness are the most common neurologic side effects (Plosker and Croom, 2005; Rains et al., 1995). Axonal neuropathy may occur after prolonged SSZ use but is very rare (Liedorp et al., 2008).

Fertility

Prolonged treatment with SSZ may universally depress semen quality (i.e., increase the number of abnormal forms and impaired sperm motility) and cause oligosperma, leading to infertility. However, the condition appears to be reversible upon discontinuation of the drug, returning to normal 2 to 3 months after cessation. SSZ has no effect on fertility in women (Cannella and O’Dell, 2017; Plosker and Croom, 2005).

Pregnancy and lactation

SSZ and sulfapyridine cross the placenta, but they do not seem to cause or increase fetal anomalies, spontaneous abortions and therefore can be safely used in women of childbearing age and pregnant women. However, it should be used with caution owing to reports of neural tube defects and hematological complications, such as hemolytic anemia in the fetus. Administration of folic acid (5 mg/day) with SSZ is recommended during pregnancy to decrease the risk of neural tube defects.

Sulfapyridine is secreted in breast milk. The American Academy of Pediatrics has classified SSZ as a drug that must be given with caution to nursing women, especially in cases of premature infants and those with G6PD deficiency due to an increased risk of hemolytic anemia and jaundice (Bokström et al., 2006; Wu and Ying, 2019).

Pulmonary

Pulmonary toxicity due to SSZ is rare. Typical presentation of SSZ-induced lung disease is new-onset dyspnea and infiltrates on chest radiography. Pulmonary pathology is variable, the commonest being eosinophilic pneumonia with peripheral eosinophilia and interstitial inflammation with or without fibrosis (Parry et al., 2002).

Monitoring

Complete blood counts and liver and renal function tests should be performed prior to commencing therapy. These tests should be repeated every 2 to 4 weeks for the first 3 months and then every 8 to 12 weeks for the next 3 months of treatment. Beyond 6 months of therapy, longer intervals (12 weeks) of monitoring are suggested. Patients should be advised to report immediately in case of fever, sore throat, malaise, or nonspecific illness (Saag et al., 2008).

Drug interactions

SSZ inhibits thio-purine methyl transferase enzyme activity and thus may potentiate azathioprine toxicity (Anstey et al., 2004). SSZ reduces the absorption of folic acid and digoxin (U.S. National Library of Medicine, 2001). Rarely, SSZ can increase the effects of oral hypoglycemic drugs and the anticoagulant effect of warfarin (Cannella and O’Dell, 2017).
Contraindications to SSZ include hypersensitivity to any component of SSZ, or with a sulfonamide or salicylate allergy (Saag et al., 2008); thrombocytopenia (platelet count <50,000/μL; Saag et al., 2008); hepatic disease (e.g., liver transaminases >2-fold the upper limit of normal, acute hepatitis B or C, untreated chronic hepatitis B; Saag et al., 2008); significant renal impairment (Saag et al., 2008); porphiria (Cannella and O’Dell, 2017); and G6PD deficiency (Cannella and O’Dell, 2017).

Discussion

SSZ is approved by the U.S. Food and Drug administration for the management of ulcerative colitis and rheumatoid arthritis. It has been used for a variety of dermatological diseases, such as psoriasis, alopecia areata, pemphigus vulgaris, urticaria, and mucus membrane pemphigoid. However, its use in dermatology is limited by the lack of randomized trials.

We could find only a few randomized controlled trials supporting its use in psoriasis (Bharti and Girgla, 1996; Gupta et al., 1990), lichen planus (Omidian et al., 2010), and pemphigus vulgaris (El Darouti et al., 2009). The use of SSZ in other dermatological diseases is largely supported by uncontrolled trials, case series, and case reports.

Conclusions

SSZ is an inexpensive drug that has immunomodulatory, anti-inflammatory, and antiproliferative properties with relatively few side effects. The wide range of applications of SSZ in varied dermatological diseases makes it an important drug in the therapeutic arsenal of a dermatologist. SSZ can be especially useful in patients who fail to respond to standard therapy or in those for whom standard therapy is contraindicated. However, the therapeutic potential of the drug in the field of dermatology needs to be further established by multicenter, large-scale randomized controlled trials.

Financial disclosures

none.

Funding

none.

Study approval

N/A.

Conflict of interest

none.

References

Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol 2008;64;2008,2008:74(6):611–3.

Akaokhi T, Namai R, Sekiyama N, Tanaka S, Hosaka S, Kondo H. Rapid induction of neutrophil apoptosis by sulfasalazine: implications of reactive oxygen species in the apoptotic process. J Leukoc Biol 1997;62:817–26.

Akil M, Amos RS. ARC of rheumatology. Rheumatoid arthritis –II: treatment. BMJ 1995;310(6898):652–4.

Alpsoy E. New evidence-based treatment approach in Behçet’s disease. Patholog Res Int 2012;2012 871019.

Anstey AV, Wakelin S, Reynolds N. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004;151:1123–32.

Artizz F, Lenk N, Deniz N, Alii N. Efficacy of sulfasalazine in discoid lupus erythematosus. Int J Dermatol 2016;35:746–8.

Bauza A, Espana A, Gil P, Lloret D, Doval FJL. Successful treatment of lichen planus with sulfasalazine in 20 patients. Int J Dermatol 2005;44(2):158–62.

Bharti R, Girgla S. Sulfasalazine in treatment of psoriasis. Indian J Dermatol Venereol Leprol 1996;62(2):87–8.

Bhat RM. Pyoderma gangrenosum: an update. Indian Dermatol Online J 2012 Jan;3(1):7–13.

Bisht S, Kullavannaiyaa P. Sulfasalazine in atrophic blanche. J Am Acad Dermatol 1993;28:275–6.

Bissonnette EY, Enciso JA, Befus AD. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-α alpha production by mast cells. J Immunol 1996;156:218–23.

Bokstrom H, Holst RM, Hafstrom O, Swolin B, Johansson ML, Brunolf G, et al. Fatal hemolytic anemia associated with maternal sulfasalazine therapy during pregnancy. Acta Obstet Gynecol Scand 2006;85(1):118–21.

Brzezinska-Wcislo LA, Wcislo-Dziadecka D. Hair diseases: a big problem on a small surface. Adv Dermatol Allergol 2016;33(5):317.

Camp RDR, Psoirasis. In: Champian RH, Burton JL, Ebling FJG, editors. Textbook of dermatology. 5th ed. Oxford: Blackwell Scientific Publications; 1992. p. 1391–457.

Cannella AC, O’Dell JR. Traditional DMARDs: methotrexate, sulfasalazine, leflunomide, hydroxychloroquine and combination therapies. In: Firestein GS, Budd R, Gabriel SE, McInnes IB, editors. Kelley’s textbook of rheumatology. 10th ed. Elsevier; 2017. p. 971–4.

Chen ML, Chlipok A, Hoang MP, Smith GP. Complete resolution of erythema elevatum diuturnum using oral sulfasalazine. Dermatol Online J 2017;23(10).

Delaporte E, Catteau B, Sabbagh N, Gesselin P, Breuillard F, Douste MS, et al. Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases. Ann Dermatol Venereol 1997;124(2):151–6.

Doan S, Leroic JF, Robin H, Prost C, Savoldelli M, Hoang-Xuan T. Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmololgy 2001;108(9):1565–8.

Dogra D, Dogra N, Gupta N, Gupta V. Sulfasalazine and pentoxifylline, a new adjuvant in young pemphigus patients: a pilot study. Indian J Dermatol Venereol Leprol 2015;22:31–7.

Dover N. Salazopyrin (sulfasalazine) treatment in scleroderma. Isr J Med Sci 1971;7(11):1301–3.

El-Darouti M, Marzouk S, Abdel Hay R, El Tawdy A, Fawzy M, Lehtea T, et al. The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol 2009;161(2):313–9.

El-Mofty M, El-Darouti M, Rasheed H, Bassiouny DA, Abdel-Halim M, Zaki NS, et al. Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative. J Dermatol Treat 2011;22:31–7.

Ellis CN, Brown MF, Voorhees JJ. Sulfasalazine for alopecia areata. J Am Acad Dermatol 2002;46(4):541–4.

Engler RJ, Squire E, Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995;74(2):155–9.

Feeley BT, Park AK, Hoyt EG, Robbins RC. Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants. J Hear Lung Transplant 1999;18(11):1088–95.

Fujiwara M, Mitsui K, Yamamoto I. Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. Jpn J Pharmacol 1990;54(2):121–31.

Gabaza EC, Taguchi O, Yamakami T, Machishi M, Itaha H, Suzuki S, et al. Pulmonary infiltrates and skin pigmentation associated with sulfasalazine. Am J Gastroenterol 1992;87(11):1654–7.

Gadangi P, Longaker M, Naime D, Levin RJ, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996;156(5):1937–40.

Ghosh S, Jain V, Chaudhari S, Mathur S. Sulfasalazine induced lichen planus in a patient of rheumatoid arthritis. Indian J Dermatol Venereol Leprol 2013;79(4):541.

Gupta AK. Sulfasalazine improves psoriasis. Arch Dermatol 1990;126(4):487.

Gupta AK, Ellis CN, Siegel MT, Voorhees JJ. Sulfasalazine: a potential psoriasis adjuvant? J Am Acad Dermatol 1989;20(5 Pt 1):797–800.

Hirohata S, Ohshima N, Yanagida T, Aramaki K. Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunopharmacol 2002;2(5):631–40.

Huber CE, Judex AG, Freyschmidt J, Feuerbach S, Schölmerich J, Müller-Ladner U. Sequential combination therapy leading to sustained remission in a patient with SAPHO syndrome. Open Rheumatol J 2009;3:18.

Jeong SH, Na HS, Park SH, Ahn YW, Chung J. Topical sulfasalazine for unresponsive oral lichen planus. Quintessence Int 2016;47(3):213–8.

Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000;3:CD000212.
Jullien D, Wolkenstein P, Roupie E, Roujeau JC, Revuz J. Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication. Arthritis Rheum 1995;38:573.

Jung JT, Jun JR, Yoo DH, Kim TH, Jung SS, Lee IH, et al. High toxicity of sulfasalazine in adult-onset Still’s. Clin Exp Rheumatol 2000;18:245–8.

Kang BY, Chung SW, Im SY, Choe YK, Kim TS. Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages. Immunology 1999;98(1):98–103.

Remlinger KA. Hematologic toxicity of drug therapy. In: Wolverton, SE, editor. Comprehensive dermatologic drug therapy. 3rd ed. 2012. p. 696.

Li M, Zhang Y, Xu H, Chen ZQ, Li YM. A case of acrodermatitis continua of Hallopeau (ACH) successfully treated with sulfasalazine. Dermatol Ther 2018a;31.

Li S, Li Z, Feng S. Low-dose sulfasalazine in a case of pyodermatitis-pyostomatitis vegetans. J Am Acad Dermatol 2018.

Liedorp M, Voskuyl AE, van Oosten BW. Axonal neuropathy with prolonged sulfasalazine use. Clin Exp Rheumatol 2008;26:671.

Marguerie L, Flipo RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 2002;69(3):275–81.

McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006;142:1337–42.

Micalizzi C, Parodi A, Rebora A. Generalized bullous morphoea: Efficacy of salazopyrin. Clin Exp Dermatol 1996;21:245–7.

Miranda MFM. Pyoderma gangrenosum treated with sulfasalazine and dapsone. Indian J Dermatol Venereol Leprol 2002;68(3):160–1.

Omidian M, Ayoobi A, Mapar M, Feily A, Cheraghian B. Efficacy of sulfasalazine in patients with human herpesvirus 6. Arch Dermatol 1998;134:1113–7.

Ordin RA, Timble H, Saini SS. Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2014;112(1):64–70.

Ozen M, Kalyoncu U. SAPHO syndrome may be treated effectively with combined drug regimen—a case report. JCRRI 2011;2:8–11.

Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002;19(4):756–64.

Ploosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 2005;65(13):1825–49.

Pruzanowski W, Stęfaniak E, Vadas P, Ramamurthy NS. Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine. Biochem Pharmacol 1997;53:1901–7.

Rains CP, Noble S, Sulfasalazine Faulds D. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50:137–56.

Rodenburg RJ, Gang A, Van Lent PL, Van De Putte LB, Van Venrooij WJ. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor expression in macrophages by inducing apoptosis. Arthritis Rheum 2000;43(9):1941–50.

Saat KG, Güm GT, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 2008;59:762–84.

Saigal R, Kansal A, Mittal M, Singh Y, Ram H. Raynaud’s phenomenon. JAPI 2010;58:309–13.

Santhanam S, Singh N. Sulfasalazine induced photo toxicity. Indian J Rheumatol 2018;13(1):64.

Smedegård G, Björk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995;34(Suppl 2):7–15.

Sobolewska B, Deuter C, Zierhut M. Current medical treatment of ocular mucous membrane pemphigoid. Ocul Surf 2013;11(4):259–66.

Svrzát N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism 1948;4(1):180–5.

Taggart AJ, McDermott BJ, Roberts SD. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. Clin Pharmacokinet 1992;23(4):311–20.

Taveira M, Selores M, Costa V, Massa A. Generalized morphea and lichen sclerosus et atrophicus successfully treated with sulfasalazine. J Eur Acad Dermatol Venereol 1999;12:283–4.

Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993;25:392–407.

Tohyama M, Yahata Y, Yasukawa M, Inagi R, Urano Y, Yamashini K, et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998;134:1113–7.

Tremblay L, de Chambrun GP, De Vroey B, Lavogiez C, Delaporte E, Colombel JF, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohn’s Colitis 2011;5:457–60.

U.S. National Library of Medicine. Azulfidine EN-tabs (sulfasalazine delayed release tablets, USP) prescribing information [Internet]. 2001 [Last accessed on 19 May 2018]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=69f541a-93d8-4428-ba45-398aad08327d1.

Watkinson C. Sulphasalazine: a review of 40 years’ experience. Drugs 1986;32(1):1–11.

Willstedt E, Lee M, Wong LC, Cooper A. Sulfasalazine and dermatitis herpetiformis. Australas J Dermatol 2005;46:101–3.

Wu TY, Ying KY. Disease modifying anti-rheumatic drugs: review of pregnancy and lactation. 2019;15(1):18–26.

Yamazaki T, Miyai E, Shibata H, Yamamoto I. Pharmacological studies of salazosulfapyridine (SASP) evaluation of anti-rheumatic action. Pharmacometrics 1991;4(6):563–74.